Dexcom Ventures
VC Fund
San Diego, United States
Dexcom Ventures is a VC fund in San Diego focused on Medical Device and Health Care. The inaugural fund will seek to identify and invest in opportunities to supplement growth in the core business and advance the development of adjacent technologies for the future.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Dexcom Ventures invests in
Stages Dexcom Ventures invests in
Countries Dexcom Ventures invests in
Investment Focus
Industry
- Medical Device 4 (57%)
- Health Care 3 (43%)
- Wearables 2 (29%)
- Biotechnology 2 (29%)
- Artificial Intelligence 2 (29%)
Stage
- Seed 2 (29%)
- Series A 2 (29%)
- Series B 2 (29%)
- Funding Round 1 (14%)
Country
- United States 4 (57%)
- Australia 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Biometry
|
Biometry is a health technology company that develops connected diagnostics and monitoring tools to support patients with chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Its platform combines patented breath sensors that measure airway inflammation biomarkers with an analytics engine to generate riskassessments, personalized risk profiles, and insights into symptom triggers and treatment response.Biometry’s solution integrates real-time biomarker data with clinical and environmental factors through a mobile app to help users and clinicians understand disease control and anticipate exacerbations. The technology is designed to enable proactive self-management and support preventive care by identifying changes in risk before symptoms worsen. The company also provides guideline-based coaching and educational content delivered through its platform to assist users in improving long-term disease control. Its products are in development and focus on enabling connected, data-driven approaches for respiratory health management. | $5M / Seed / Nov 12, 2024 | |
Signos
|
Signos is on a mission to tackle the obesity epidemic via healthy habits, glucose level stabilization, and AI. Signos combines continuous glucose information with an AI-enhanced app to offer revolutionary continuous data and recommendations designed to drive healthy and sustained weight loss. With over 75% of the American population overweight orobese, Signos provides a new way for people to act on their body’s unique response to what they eat to lose weight and kickstart a healthier life | $20M / Series B / Oct 21, 2023 | |
MedCrypt
|
MedCrypt is a medical device company that provides data security as a service to medical device OEMs. From medical imaging device to implantable devices like pacemakers, MedCrypt ensures that devices act only on instructions from trusted sources. It brings security features to medical devices, from pacemakers to surgical robots, in a few lines ofcode. The company enables engineers to implement these security features properly as quickly as possible, allowing them to get back to designing life-changing clinical features.MedCrypt was founded in 2016 and is headquartered in Encinitas, California, United States. | Series B / Jan 24, 2023 | |
Nutromics
|
Nutromics is a MedTech company revolutionising healthcare through continuous real time molecular monitoring. Our Smart Patch biosensor platform will solve some of the biggest healthcare challenges we face today in the fields of chronic disease prevention, chronic disease management, acute diseases and Therapeutic Drug Monitoring. | Sep 08, 2022 | |
|
Nutromics
|
Nutromics is a MedTech company revolutionising healthcare through continuous real time molecular monitoring. Our Smart Patch biosensor platform will solve some of the biggest healthcare challenges we face today in the fields of chronic disease prevention, chronic disease management, acute diseases and Therapeutic Drug Monitoring. | $14M / Seed / Sep 08, 2022 | |
Epitel
|
Epitel is a digital health company developing a wearable, wireless EEG monitoring platform to provide accessible, affordable, and reliable for seizure detection. | $12.5M / Series A / Feb 16, 2022 | |
|
Signos
|
Signos is on a mission to tackle the obesity epidemic via healthy habits, glucose level stabilization, and AI. Signos combines continuous glucose information with an AI-enhanced app to offer revolutionary continuous data and recommendations designed to drive healthy and sustained weight loss. With over 75% of the American population overweight orobese, Signos provides a new way for people to act on their body’s unique response to what they eat to lose weight and kickstart a healthier life | $13M / Series A / Nov 10, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Dexcom Ventures invest in?
Dexcom Ventures invests primarily in Medical Device, Health Care and Wearables startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dexcom Ventures last invest?
The most recent investment recorded for Dexcom Ventures closed in Nov 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
